Genomics AI Startup MNM Bioscience Secures Almost $1 Million in Eureka Eurostars Funding for AI-Based Cancer Patient Stratification Tool
BOSTON–(BUSINESS WIRE)–MNM Bioscience, a tech start-up using genomic data and artificial intelligence algorithms to develop personalized medicine solutions, has been awarded an $800,000 grant from Eureka’s Eurostars program. The program is a dedicated funding instrument for innovative SMEs and will support the development of MNM’s unique patient stratification tool for ovarian cancer patients.
This ambitious project will be carried out in consortium between MNM Bioscience and Macrogen Europe, a Dutch company specializing in DNA sequencing and bioinformatics services.
The tool, named PARPiNDx (PARPindex), aims at better classification of patients for targeted cancer therapy, increasing the chances of fighting the disease through the rapid implementation of the highly effective drug. The tool selects patients who will respond to PARP inhibitors, a breakthrough family of drugs successfully administered to patients with ovarian cancer, as well as several other types of cancer, including pancreatic, breast and and prostate.
PARPiNDx is based on genomic data derived from the whole genome sequencing data analyzed by AI-driven algorithms. PARPiNDx not only selects patients who will respond to PARPi, it also identifies patients with intrinsic resistance to PARPi.
The consortium agreement was signed on March 24, 2022.